<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144460">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01699685</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237ACH01</org_study_id>
    <secondary_id>2012-002362-13</secondary_id>
    <nct_id>NCT01699685</nct_id>
  </id_info>
  <brief_title>Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.</brief_title>
  <acronym>SYNERGY</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to evaluate the effect of QAB149

        -  NVA237 vs. QAB149 on static lung hyperinflation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blinded, single-dose, cross-over,
      placebo-controlled study. The primary endpoint was chosen to demonstrate the superiority of
      a single-dose of the combined inhalation vs. the mono inhalation regarding the Inspiratory
      Capacity (IC) peak value. A total of 78 patients will be randomized to complete two visits
      with two single doses of treatment. Patients will be randomized in a cross-over manner.
      Treatment visits will be separated by a study medication wash-out period.Treatments will be
      administered in a blinded fashion.

      The patients will be male and female patients, ≥40 years of age, with a documented diagnosis
      of moderate or severe COPD according to Global Initiative for Chronic Obstructive Lung
      Disease (GOLD) criteria and &gt;10-pack years history of smoking, FEV1 &lt;80% and ≥30% of the
      predicted normal value.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Inspiratory Capacity (IC) peak value</measure>
    <time_frame>maximum value within 4h after inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate superiority of a single-dose of the combined inhalation of QAB149  and NVA237 vs. QAB149 alone regarding the Inspiratory Capacity (IC) peak value (defined as maximum value within 4h after inhalation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in one second (FEV1)</measure>
    <time_frame>within 4h after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>Key Secondary Objective: • To compare the efficacy of the combined inhalation of QAB149 and NVA237 vs. QAB149 alone regarding FEV1 over 4h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory Capacity (IC)</measure>
    <time_frame>within 4h after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the efficacy of the combined inhalation of QAB149 and  NVA237 vs. QAB149 alone regarding the Inspiratory Capacity (IC) over 4h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Volume Capacity (FVC)</measure>
    <time_frame>within 4h after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the efficacy of the combined inhalation of QAB149 and NVA237 vs. QAB149 alone regarding Forced Volume Capacity (FVC) over 4h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lung Capacity (TLC)</measure>
    <time_frame>within 4h after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the efficacy of the combined inhalation of QAB149 and NVA237 vs. QAB149 alone regarding of Total Lung Capacity (TLC) over 4h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Resistance (Raw)</measure>
    <time_frame>within 4h after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the efficacy of the combined inhalation of QAB149 and NVA237 vs. QAB149 alone regarding Airway Resistance (Raw) over 4h.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease: COPD</condition>
  <arm_group>
    <arm_group_label>QAB149 + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QAB149 + NVA237</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAB149</intervention_name>
    <description>Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI</description>
    <arm_group_label>QAB149 + Placebo</arm_group_label>
    <arm_group_label>QAB149 + NVA237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI</description>
    <arm_group_label>QAB149 + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237</intervention_name>
    <description>Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI</description>
    <arm_group_label>QAB149 + NVA237</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female patients, ≥40 years of age, with a documented diagnosis of moderate
             or severe COPD according to Global Initiative for Chronic Obstructive Lung Disease
             (GOLD) criteria and &gt;10-pack year history of smoking

          -  FEV1 &lt;80% and ≥30% of the predicted normal value who have signed an informed consent
             form prior to the initiation of any study-related procedure

        Exclusion criteria:

          -  No COPD exacerbations within 6 weeks prior to dosing

          -  No concomitant lung disease such as asthma

          -  Nno requirement for long term oxygen treatment or history of lung reduction surgery

          -  No medical conditions that would interfere with the performance of spirometry

          -  No other medical condition that in the opinion of the investigator may cause the
             patient to be unsuitable for completion of the study or place the patient at
             potential risk form being in the study e.g. uncontrolled hypertension or unstable
             ischemic heart disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Wild, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Corinne Wild, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Brutsche, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital St. Gallen, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals, PhD</last_name>
    <phone>+41613241111</phone>
    <email>corinne.wild@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals, Dr. med.</last_name>
    <phone>+41 31 377 53 62</phone>
    <email>Stephanie.Juritz@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Faltigberg-Wald</city>
        <state>ZH</state>
        <zip>8639</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barmelweid</city>
        <zip>5017</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3013</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Crans-Montana</city>
        <zip>3963</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heiligenschwendi</city>
        <zip>3625</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Walenstadtberg</city>
        <zip>8881</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>September 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe COPD patients are included</keyword>
  <keyword>NVA</keyword>
  <keyword>QAB</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
